Program
relacorilant
Also written as “Relacorilant”, “CORT125134” and “Relacorilant 150 mg”.
Its studies are mostly in Cushing Syndrome · Ovarian Neoplasms · Carcinoma, Pancreatic Ductal · Adrenocortical Carcinoma · Pancreatic Neoplasms, led by Corcept Therapeutics.
Drug pageRelacorilant: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Corcept Therapeutics | 223 open or running | phase 3since Sep 27, 2018 | Apr 11, 2016 | Dec 2026phase 2 · NCT03604198 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 5 earlier studies, Apr 11, 2016 to Jan 23, 2018.
- Dec 9, 2016Named relacorilantINNProposed as its International Nonproprietary Name in WHO's List 116 · before, CORT125134
- Mar 1, 2018Phase 1 study in HealthyNCT03457597 · 27 enrolled · United States
- Apr 3, 2018Phase 1 study in HealthyNCT03512548 · 52 enrolled · United States
- May 1, 2018Phase 2 study in Cushing SyndromeNCT03604198 · 125 enrolled · United States, Austria, Canada and more
- May 17, 2018Phase 1 study in HealthyNCT03540836 · 30 enrolled · United States
- Sep 27, 2018Phase 3 study in Cushing SyndromeNCT03697109 · 152 enrolled · United States, Austria, Bulgaria and more
- Dec 13, 2018Phase 2 study in Ovarian NeoplasmsNCT03776812 · 178 enrolled · United States, Belgium, Canada and more
- Feb 27, 2020Phase 3 study in Cushing SyndromeNCT04308590 · 137 enrolled · United States, Austria, Bulgaria and more
- Mar 13, 2020Phase 3 study in Pancreatic NeoplasmsNCT04329949 · 43 enrolled · United States
- Apr 30, 2020Phase 1 study in Adrenocortical CarcinomaNCT04373265 · 15 enrolled · United States
- Jan 29, 2021Phase 1 study in HealthyNCT04795479 · 36 enrolled · United States
- Feb 4, 2022Phase 3 study in Ovarian NeoplasmsNCT05257408 · 381 enrolled · United States, Argentina, Australia and more
- Apr 18, 2022Phase 1 study in Cushing SyndromeNCT05347979 · 30 enrolled · United States
- Oct 17, 20234 phase 1 studiesNCT06094790, NCT06094738, NCT06094725 and 1 more
- Nov 3, 2025Phase 2 study in AdenocarcinomaNCT07259317 · 80 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Cushing SyndromeNCT03604198
- Sep 2027Primary completion: phase 2 study in AdenocarcinomaNCT07259317
TargetBeta
“Glucocorticoid receptor antagonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07259317Adenocarcinoma · United States | 2 | Recruiting | Sep 2027 | 80 |
| NCT06094790Healthy · United States | 1 | Completed | Nov 15, 2017 | 32 |
| NCT06094738Healthy · United States | 1 | Completed | Nov 16, 2020 | 30 |
| NCT06094725Hepatic Impairment · United States | 1 | Completed | Dec 14, 2020 | 30 |
| NCT06094712Healthy · United States | 1 | Completed | Apr 27, 2016 | 8 |
| NCT05347979Cushing Syndrome · United States | 1 | Completed | Jul 19, 2022 | 30 |
| NCT05257408Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 31, 2025 | 381 |
| NCT04795479Healthy · United States | 1 | Completed | May 17, 2021 | 36 |
| NCT04373265Adrenocortical Carcinoma · United States | 1 | Completed | Oct 17, 2023 | 15 |
| NCT04329949Pancreatic Neoplasms · United States | 3 | Terminated | Aug 23, 2021 | 43 |
| NCT04308590Cushing Syndrome · United States, Austria, Bulgaria and more | 3 | Completed | Sep 19, 2024 | 137 |
| NCT03776812Ovarian Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Mar 16, 2021 | 178 |
| NCT03697109Cushing Syndrome · United States, Austria, Bulgaria and more | 3 | Completed | Apr 8, 2024 | 152 |
| NCT03540836Healthy · United States | 1 | Completed | Jul 16, 2018 | 30 |
| NCT03604198Cushing Syndrome · United States, Austria, Canada and more | 2 | Active, not recruiting | Dec 2026 | 125 |
| NCT03512548Healthy · United States | 1 | Completed | Jul 29, 2019 | 52 |
| NCT03457597Healthy · United States | 1 | Completed | Apr 15, 2018 | 27 |
| NCT03442621Healthy · United States | 1 | Completed | Feb 28, 2018 | 30 |
| NCT03508635Healthy · United Kingdom | 1 | Completed | Dec 2015 | 130 |
| NCT03067376Healthy · United Kingdom | 1 | Completed | Sep 2016 | 9 |
| NCT02804750Cushing Syndrome · United States, Hungary, Italy and more | 2 | Completed | Sep 2018 | 35 |
| NCT02762981Triple Negative Breast Neoplasms · United States | 2 | Completed | May 12, 2020 | 85 |
How it is read
Names in the registry
- “Relacorilant”, 9 entries
- “CORT125134”, 3 entries
- “relacorilant”, 1 entry
- “Relacorilant 150 mg”, 1 entry
- “Relacorilant, 100 mg and 25 mg”, 1 entry
Conditions, from the studies’ own filings
- Cushing Syndrome, 5 studies
- Ovarian Neoplasms, 2 studies
- Carcinoma, Pancreatic Ductal, 1 study
- Adrenocortical Carcinoma, 1 study
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.